Trials / No Longer Available
No Longer AvailableNCT06004128
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Invivyd, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VYD222 | Monoclonal antibody |
Timeline
- First posted
- 2023-08-22
- Last updated
- 2024-06-03
Source: ClinicalTrials.gov record NCT06004128. Inclusion in this directory is not an endorsement.